Morgan Stanley raised the firm’s price target on Halozyme (HALO) to $80 from $75 and keeps an Overweight rating on the shares. Halozyme’s 2025 EPS guidance has increased by 20% since January, driven by partnered products and cost discipline, notes the analyst, who adjusted the firm’s earnings outlook to consider the higher 2025 base and its implications for future long-term earnings guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HALO:
- Halozyme’s Strong Financial Performance and Growth Potential Justifies Buy Rating
- Halozyme Therapeutics’ Earnings Call Highlights Robust Growth
- Halozyme’s Strong Financial Performance and Growth Prospects Lead to Buy Rating and Increased Price Target
- Halozyme’s Strong Financial Performance and Growth Prospects Lead to Buy Rating
- Halozyme price target raised to $75 from $72 at H.C. Wainwright